OI
MCID: ORT004
MIFTS: 63

Orthostatic Intolerance (OI)

Categories: Cardiovascular diseases, Genetic diseases, Mental diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Orthostatic Intolerance

MalaCards integrated aliases for Orthostatic Intolerance:

Name: Orthostatic Intolerance 56 74 73 36 29 13 6 17
Mitral Valve Prolapse 12 74 36 29 54 6 42 43 15 62
Neurocirculatory Asthenia 56 12 43 15 71
Mitral Valve Prolapse Syndrome 56 71
Irritable Heart 56 71
Familial Orthostatic Tachycardia Due to Norepinephrine Transporter Deficiency 58
Postural Orthostatic Tachycardia Syndrome Due to Net Deficiency 58
Cardiovascular Malfunction Arising from Mental Factors 12
Orthostatic Intolerance Due to Net Deficiency 58
Mitral Valve Prolapse, Familial, X-Linked 71
Myxomatous Mitral Valve Prolapse 12
Systolic Click-Murmur Syndrome 12
Pots Due to Net Deficiency 58
Intolerance, Orthostatic 39
Cardiovascular Neurosis 12
Mitral Leaflet Syndrome 12
Floppy Mitral Valve 12
Da Costa's Syndrome 12
Krishaber's Disease 12
Barlow's Syndrome 12
Soldiers Heart 56
Oi 73

Characteristics:

Orphanet epidemiological data:

58

HPO:

31
orthostatic intolerance:
Inheritance autosomal dominant inheritance


Classifications:

Orphanet: 58  
Rare neurological diseases


External Ids:

Disease Ontology 12 DOID:11569 DOID:988
OMIM 56 604715
ICD9CM 34 306.2
NCIt 49 C50655
ICD10 via Orphanet 33 I95.1
Orphanet 58 ORPHA443236
SNOMED-CT via HPO 68 263681008
UMLS 71 C0026267 C0027821 C2930833 more

Summaries for Orthostatic Intolerance

KEGG : 36 Mitral valve prolapse (MVP) is a very common clinical condition that refers to a systolic billowing of one or both mitral valve leaflets into the left atrium. MVP can be associated with significant mitral regurgitation (MR), bacterial endocarditis, congestive heart failure, and even sudden death. According to the presently used echocardiographic criteria, MVP is defined as an upward displacement of the mitral leaflets that exceeds 2 mm during diastole. In classical MVP, the leaflets' maximal thickness is >5 mm, whereas in non-classical MVP it remains <5 mm. MVP may or may not have associated mitral regurgitation. MVP can be distinguished into primary or nonsyndromic MVP and secondary or syndromic MVP. In the latter case, MVP occurs in the presence of connective tissue disorders such as Marfan syndrome (MFS) [DS:H00653], Loeys-Dietz syndrome [DS:H00800], Ehlers-Danlos syndrome [DS:H00802], and osteogenesis imperfecta [DS:H00506]. Nonsyndromic MVP can be sporadic or familial, demonstrating autosomal dominant and X-linked inheritance. Three different loci on chromosomes 16, 11 and 13 have been found to be linked to MVP. Another locus on chromosome X has been found to cosegregate with a rare form of MVP called X-linked myxomatous valvular dystrophy.

MalaCards based summary : Orthostatic Intolerance, also known as mitral valve prolapse, is related to postural orthostatic tachycardia syndrome and mitral valve insufficiency, and has symptoms including angina pectoris, edema and chest pain. An important gene associated with Orthostatic Intolerance is SLC6A2 (Solute Carrier Family 6 Member 2), and among its related pathways/superpathways are cGMP-PKG signaling pathway and AGE-RAGE signaling pathway in diabetic complications. The drugs Methylprednisolone and Methylprednisolone hemisuccinate have been mentioned in the context of this disorder. Affiliated tissues include heart, testes and kidney, and related phenotypes are orthostatic tachycardia and cardiovascular system

Disease Ontology : 12 A mitral valve disease where one or both of the cusps of the mitral valve bulge or collapse backward in the left atrium during systole.

MedlinePlus : 42 Mitral valve prolapse (MVP) occurs when one of your heart's valves doesn't work properly. The flaps of the valve are "floppy" and don't close tightly. Most people who have the condition are born with it. It also tends to run in families. Most of the time, MVP doesn't cause any problems. Rarely, blood can leak the wrong way through the floppy valve. This can cause Palpitations (feelings that your heart is skipping a beat, fluttering, or beating too hard or too fast) Shortness of breath Cough Fatigue, dizziness, or anxiety Migraine headaches Chest discomfort Most people who have mitral valve prolapse (MVP) don't need treatment because they don't have symptoms and complications. If you need treatment for MVP, medicines can help relieve symptoms or prevent complications. Very few people will need surgery to repair or replace the mitral valve. MVP puts you at risk for infective endocarditis, a kind of heart infection. To prevent it, doctors used to prescribe antibiotics before dental work or certain surgeries. Now, only people at high risk of endocarditis need the antibiotics. NIH: National Heart, Lung, and Blood Institute

UniProtKB/Swiss-Prot : 73 Orthostatic intolerance: Syndrome characterized by lightheadedness, fatigue, altered mentation and syncope. It is associated with postural tachycardia. Plasma norepinephrine concentration is abnormally high.

PubMed Health : 62 About mitral valve prolapse: Mitral (MI-tral) valve prolapse (MVP) is a condition in which the heart's mitral valve doesn't work well. The flaps of the valve are "floppy" and don't close tightly. These flaps normally help seal or open the valve. Much of the time, MVP doesn't cause any problems. Rarely, blood can leak the wrong way through the floppy valve. This can lead to palpitations, shortness of breath, chest pain, and other symptoms. (Palpitations are feelings that your heart is skipping a beat, fluttering, or beating too hard or too fast.)

Wikipedia : 74 Mitral valve prolapse (MVP) is a valvular heart disease characterized by the displacement of an... more...

More information from OMIM: 604715

Related Diseases for Orthostatic Intolerance

Diseases in the Orthostatic Intolerance family:

Chronic Orthostatic Intolerance

Diseases related to Orthostatic Intolerance via text searches within MalaCards or GeneCards Suite gene sharing:

(showing 487, show less)
# Related Disease Score Top Affiliating Genes
1 postural orthostatic tachycardia syndrome 34.5 SLC6A2 FBN1
2 mitral valve insufficiency 31.9 PDLIM1 MIR423 FBN1 ELN
3 tricuspid valve prolapse 31.8 PDLIM1 FBN1
4 coronary artery anomaly 31.8 NOS3 ELN EDN1 AGTR1
5 arteries, anomalies of 31.7 NOS3 MIR423 EDN1 AGTR1
6 pulmonary hypertension 31.7 TRPC1 NOX4 NOS3 EDN1 AGTR1
7 connective tissue disease 31.6 PLOD1 MIR423 FBN1 ELN EDN1
8 hypermobile ehlers-danlos syndrome 31.4 PLOD1 FBN1
9 patent ductus arteriosus 1 31.4 FBN1 ELN EDN1
10 arteriosclerosis 31.3 NOS3 FBN1 ELN EDN1
11 impotence 31.3 POMC NOS3 EDN1
12 heart valve disease 31.3 PDLIM1 MIR423 FBN1 ELN EDN1
13 pulmonary edema 31.2 NOS3 EDN1 AGTR1
14 intraocular pressure quantitative trait locus 31.2 FBN1 ELN EDN1 ACHE
15 coronary artery vasospasm 31.1 NOS3 EDN1 ADRA2B ADRA2A
16 brittle bone disorder 31.1 PLOD1 FBN1 ELN
17 scleroderma, familial progressive 31.1 FBN1 EDN1
18 body mass index quantitative trait locus 11 31.1 SLC6A2 POMC NOS3 MIR423 EDN1 ADRA2A
19 nonarteritic anterior ischemic optic neuropathy 31.1 NOS3 EDN1 AGTR1
20 atrial heart septal defect 31.1 FBN1 ELN EDN1
21 myocardial infarction 31.0 NOS3 MIR423 ELN EDN1 AGTR1 ADRA2B
22 mitral valve disease 31.0 NOS3 MIR423 FBN1 ELN AGTR1
23 coronary heart disease 1 31.0 NOS3 EDN1 AGTR1
24 portal hypertension 31.0 NOS3 ELN EDN1 AGTR1
25 collagen disease 31.0 PLOD1 FBN1 ELN EDN1
26 pulmonary valve insufficiency 31.0 FBN1 EDN1
27 pain agnosia 31.0 POMC ADRA2B ADRA2A
28 renovascular hypertension 31.0 NOS3 EDN1 AGTR1
29 loeys-dietz syndrome 30.9 FBN1 ELN AGTR1
30 aortic valve disease 1 30.9 PLOD1 NOS3 FBN1 ELN EDN1 AGTR1
31 aortic valve disease 2 30.9 PDLIM1 NOS3 MIR423 FBN1 ELN
32 open-angle glaucoma 30.8 NOS3 ELN EDN1
33 heart disease 30.7 NOS3 MIR423 FBN1 ELN EDN1 AGTR1
34 marfan syndrome 30.7 FBN1 ELN AGTR1
35 hypertension, essential 30.6 TRPC1 SLC7A1 SLC6A2 POMC NOX4 NOS3
36 mitral valve prolapse 2 13.1
37 mitral valve prolapse 3 13.0
38 chronic orthostatic intolerance 12.7
39 mitral valve prolapse, familial, autosomal dominant 12.6
40 hypogonadism-mitral valve prolapse-intellectual disability syndrome 12.6
41 osteogenesis imperfecta, type v 12.4
42 osteogenesis imperfecta, type iv 12.4
43 osteogenesis imperfecta, type ii 12.4
44 brachydactyly-mesomelia-intellectual disability-heart defects syndrome 12.3
45 osteogenesis imperfecta, type iii 12.3
46 osteogenesis imperfecta, type i 12.2
47 osteogenesis imperfecta, type viii 12.1
48 osteogenesis imperfecta, type xiii 12.1
49 osteogenesis imperfecta, type xiv 12.1
50 osteogenesis imperfecta, type xv 12.1
51 osteogenesis imperfecta, type vii 12.0
52 osteogenesis imperfecta, type xi 12.0
53 osteogenesis imperfecta, type x 12.0
54 mitral valve prolapse 1 11.9
55 osteogenesis imperfecta, type vi 11.9
56 mitral valve prolapse, familial, x-linked 11.9
57 osteogenesis imperfecta, type xii 11.9
58 cantalamessa baldini ambrosi syndrome 11.9
59 mccune-albright syndrome 11.8
60 dental anomalies and short stature 11.8
61 spastic ataxia, charlevoix-saguenay type 11.8
62 ehlers-danlos syndrome, classic-like, 2 11.7
63 dentinogenesis imperfecta 11.6
64 contractural arachnodactyly, congenital 11.5
65 polycystic kidney disease 1 with or without polycystic liver disease 11.5
66 ehlers-danlos syndrome, cardiac valvular type 11.5
67 lymphedema-hypoparathyroidism syndrome 11.5
68 frank-ter haar syndrome 11.5
69 progressive external ophthalmoplegia with mitochondrial dna deletions, autosomal recessive 1 11.5
70 multicentric osteolysis, nodulosis, and arthropathy 11.5
71 chromosome 17q11.2 deletion syndrome 11.5
72 microphthalmia, syndromic 2 11.5
73 osteogenesis imperfecta, type ix 11.4
74 col1a1/2 osteogenesis imperfecta 11.4
75 high bone mass osteogenesis imperfecta 11.4
76 cole-carpenter syndrome 11.3
77 ovarian hyperstimulation syndrome 11.3
78 osteogenesis imperfecta, type xvi 11.2
79 ehlers-danlos/osteogenesis imperfecta syndrome 11.1
80 syncope 10.9
81 neurotic disorder 10.9
82 pure autonomic failure 10.9
83 persistent fetal circulation syndrome 10.7 POMC NOS3 EDN1
84 late-onset focal dermal elastosis 10.7 FBN1 ELN
85 pseudoxanthoma elasticum-like papillary dermal elastolysis 10.7 FBN1 ELN
86 acute mountain sickness 10.7 NOS3 EDN1 AGTR1
87 agnosia 10.7 POMC ADRA2B ADRA2A
88 subacute leukemia 10.7 SLC7A1 POMC
89 diaphragm disease 10.7 NOS3 ELN EDN1
90 renal hypertension 10.7 NOS3 EDN1 AGTR1
91 chronic actinic dermatitis 10.7 FBN1 ELN
92 cerebral arterial disease 10.7 NOS3 ELN EDN1
93 familial abdominal aortic aneurysm 10.7 FBN1 ELN
94 mid-dermal elastolysis 10.7 FBN1 ELN
95 chronic mountain sickness 10.7 NOS3 EDN1
96 causalgia 10.7 ADRA2B ADRA2A
97 sexual disorder 10.7 POMC NOS3 EDN1 ADRA2B ADRA2A
98 ureteric orifice cancer 10.7 SLC7A1 FBN1 ELN
99 eclampsia 10.7 NOS3 EDN1 AGTR1
100 supravalvular aortic stenosis 10.7 PDLIM1 FBN1 ELN
101 malignant renovascular hypertension 10.7 EDN1 AGTR1
102 diaphragmatic hernia, congenital 10.7 NOS3 FBN1 ELN EDN1
103 homocysteinemia 10.7 NOS3 FBN1 ELN
104 glaucoma, primary open angle 10.6 FBN1 ELN EDN1
105 malignant hypertensive renal disease 10.6 EDN1 AGTR1
106 aortic aneurysm, familial thoracic 1 10.6 FBN1 ELN AGTR1
107 autonomic dysfunction 10.6
108 atherosclerosis susceptibility 10.6 NOS3 ELN EDN1 AGTR1
109 dowling-degos disease 1 10.6 POMC EDN1
110 bladder diverticulum 10.6 PDLIM1 ELN
111 kidney hypertrophy 10.6 NOX4 NOS3
112 chronic fatigue syndrome 10.6
113 prostatic adenoma 10.6 ADRA2B ADRA2A
114 autosomal recessive cutis laxa type i 10.6 FBN1 ELN
115 hyperlipoproteinemia, type iii 10.6
116 cardiovascular system disease 10.6 NOS3 MIR423 ELN EDN1 AGTR1
117 progressive familial heart block, type ia 10.6
118 tricuspid valve insufficiency 10.6
119 anorexia nervosa 10.5
120 aortic valve insufficiency 10.5
121 pulmonary fibrosis, idiopathic 10.5 NOX4 MIR423 ELN EDN1
122 dysautonomia 10.5
123 mitral valve stenosis 10.5
124 ischemia 10.5
125 scleredema adultorum 10.5 POMC FBN1
126 keratoconus 10.5
127 aneurysm 10.5
128 atrial septal aneurysm 10.5
129 chronic kidney disease 10.5 POMC NOS3 EDN1 AGTR1
130 progressive familial heart block, type ib 10.5
131 right bundle branch block 10.5
132 diabetes mellitus, noninsulin-dependent 10.5 POMC NOX4 NOS3 MIR423 EDN1 AGTR1
133 male reproductive organ benign neoplasm 10.5 ADRA2B ADRA2A
134 autosomal recessive cutis laxa type ii classic type 10.5 FBN1 ELN
135 wolff-parkinson-white syndrome 10.5
136 pneumothorax 10.5
137 ventricular fibrillation, paroxysmal familial, 1 10.5
138 pneumothorax, primary spontaneous 10.4
139 transient cerebral ischemia 10.4
140 myotonic dystrophy 10.4
141 graves disease 1 10.4
142 infective endocarditis 10.4
143 endocarditis 10.4
144 pseudoxanthoma elasticum 10.4
145 atrial fibrillation 10.4
146 specific developmental disorder 10.4 SLC6A2 POMC ADRA2A
147 panic disorder 10.4
148 goiter 10.4
149 dilated cardiomyopathy 10.4
150 cardiac conduction defect 10.3
151 cardiac arrest 10.3
152 osteochondrosis 10.3
153 myocarditis 10.3
154 renal artery disease 10.3 NOS3 AGTR1
155 fainting 10.3
156 kearns-sayre syndrome 10.3
157 left bundle branch hemiblock 10.3
158 hemiplegia 10.3
159 branch retinal artery occlusion 10.3
160 rheumatic disease 10.3
161 aortic valve prolapse 10.3
162 retinal artery occlusion 10.3
163 amaurosis fugax 10.3
164 multiple system atrophy 1 10.3
165 ehlers-danlos syndrome 10.3
166 pectus excavatum 10.3
167 scoliosis 10.3
168 heart septal defect 10.3
169 atrial tachyarrhythmia with short pr interval 10.2
170 major affective disorder 1 10.2
171 fibrosis of extraocular muscles, congenital, 1 10.2
172 hernia, hiatus 10.2
173 systemic lupus erythematosus 10.2
174 multinucleated neurons, anhydramnios, renal dysplasia, cerebellar hypoplasia, and hydranencephaly 10.2
175 fragile x syndrome 10.2
176 striatal degeneration, autosomal dominant 2 10.2
177 sensorineural hearing loss 10.2
178 von willebrand's disease 10.2
179 chronic progressive external ophthalmoplegia 10.2
180 endomyocardial fibrosis 10.2
181 inferior myocardial infarction 10.2
182 arthritis 10.2
183 sickle cell disease 10.2
184 dysphagia 10.2
185 primary orthostatic hypotension 10.2
186 osteoporosis 10.2
187 bone mineral density quantitative trait locus 8 10.2
188 bone mineral density quantitative trait locus 15 10.2
189 cardiac arrhythmia 10.2
190 atrioventricular block 10.2
191 atrial standstill 1 10.2
192 hypercholesterolemia, familial, 1 10.2
193 hypertriglyceridemia, familial 10.2
194 panic disorder 1 10.2
195 spinal arachnoiditis 10.2
196 body mass index quantitative trait locus 9 10.2
197 body mass index quantitative trait locus 8 10.2
198 body mass index quantitative trait locus 4 10.2
199 body mass index quantitative trait locus 10 10.2
200 body mass index quantitative trait locus 7 10.2
201 body mass index quantitative trait locus 12 10.2
202 body mass index quantitative trait locus 14 10.2
203 body mass index quantitative trait locus 18 10.2
204 body mass index quantitative trait locus 19 10.2
205 body mass index quantitative trait locus 20 10.2
206 deficiency anemia 10.2
207 brucellosis 10.2
208 social phobia 10.2
209 arachnoiditis 10.2
210 hypochondriasis 10.2
211 bronchitis 10.2
212 hyperthyroidism 10.2
213 hypoxia 10.2
214 motion sickness 10.2
215 autonomic neuropathy 10.2
216 headache 10.2
217 stickler syndrome, type i 10.2
218 autoimmune disease 10.2
219 pelvic organ prolapse 10.2
220 cardiomyopathy, familial hypertrophic, 1 10.2
221 factor x deficiency 10.2
222 muscular dystrophy, duchenne type 10.2
223 branchiootic syndrome 1 10.2
224 psoriatic arthritis 10.2
225 major depressive disorder 10.2
226 ataxia, combined cerebellar and peripheral, with hearing loss and diabetes mellitus 10.2
227 arrhythmogenic right ventricular cardiomyopathy 10.2
228 brachydactyly 10.2
229 aphasia 10.2
230 idiopathic scoliosis 10.2
231 left ventricular noncompaction 10.2
232 stickler syndrome 10.2
233 amnestic disorder 10.2
234 hemopericardium 10.2
235 hypertensive heart disease 10.2
236 pericardial effusion 10.2
237 visual epilepsy 10.2
238 allergic hypersensitivity disease 10.2
239 chagas disease 10.2
240 mental depression 10.2
241 optic nerve disease 10.2
242 ectodermal dysplasia 10.2
243 protein s deficiency 10.2
244 epidermolysis bullosa 10.2
245 neuromuscular disease 10.2
246 vasculitis 10.2
247 eating disorder 10.2
248 lupus erythematosus 10.2
249 dyskinesia of esophagus 10.2
250 bidirectional tachycardia 10.2
251 sudden sensorineural hearing loss 10.2
252 depression 10.2
253 myotonia 10.2
254 seizure disorder 10.2
255 neonatal marfan syndrome 10.2
256 quadricuspid aortic valve 10.2
257 prolapse of urethra 10.1 SLC7A1 ELN
258 angina pectoris 10.1
259 ventricular septal defect 10.1
260 relapsing polychondritis 10.1
261 myopathy 10.1
262 subvalvular aortic stenosis 10.1
263 congestive heart failure 10.1
264 hypertrophic cardiomyopathy 10.1
265 aneurysm of sinus of valsalva 10.1
266 ehlers-danlos syndrome, hypermobility type 10.1
267 migraine with or without aura 1 10.1
268 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 10.1
269 hypermobility syndrome 10.1
270 fibromyalgia 10.1
271 neuropathy 10.1
272 human immunodeficiency virus type 1 10.1
273 helix syndrome 10.1
274 cryptococcal meningitis 10.1
275 respiratory failure 10.1
276 neutropenia 10.1
277 cholera 10.1
278 progressive multifocal leukoencephalopathy 10.1
279 dentin dysplasia 10.1
280 speech disorder 10.1
281 meningitis 10.1
282 tuberculous meningitis 10.1
283 swallowing disorders 10.1
284 stroke, ischemic 10.0
285 sinoatrial node disease 10.0
286 rheumatic heart disease 10.0
287 isolated ectopia lentis 10.0
288 charcot-marie-tooth disease 10.0
289 tooth disease 10.0
290 graves' disease 10.0
291 sick sinus syndrome 10.0
292 generalized anxiety disorder 10.0
293 hypothyroidism 10.0
294 rheumatic fever 10.0
295 pericarditis 10.0
296 epilepsy 10.0
297 long qt syndrome 10.0
298 aortic aneurysm 10.0
299 intracranial embolism 10.0
300 subacute bacterial endocarditis 10.0
301 agoraphobia 10.0
302 cerebrovascular disease 10.0
303 irritable bowel syndrome 10.0
304 muscular dystrophy 10.0
305 hypoglycemia 10.0
306 chaotic atrial tachycardia 10.0
307 progressive muscular dystrophy 10.0
308 multifocal atrial tachycardia 10.0
309 hypokalemia 10.0
310 gastroesophageal reflux 10.0
311 coarctation of aorta 10.0
312 fibromuscular dysplasia 10.0
313 gilbert syndrome 10.0
314 hypertaurinuric cardiomyopathy 10.0
315 lentiginosis, inherited patterned 10.0
316 progressive external ophthalmoplegia with mitochondrial dna deletions, autosomal dominant 1 10.0
317 myotonic dystrophy 1 10.0
318 nipples, supernumerary 10.0
319 platelet aggregation, spontaneous 10.0
320 rheumatoid arthritis 10.0
321 scoliosis, isolated 1 10.0
322 stiff skin syndrome 10.0
323 chromosome 2q35 duplication syndrome 10.0
324 tetralogy of fallot 10.0
325 down syndrome 10.0
326 von willebrand disease, type 1 10.0
327 atrioventricular dissociation 10.0
328 camptodactyly with muscular hypoplasia, skeletal dysplasia, and abnormal palmar creases 10.0
329 diabetes mellitus, insulin-dependent 10.0
330 ectodermal dysplasia 10b, hypohidrotic/hair/tooth type, autosomal recessive 10.0
331 pycnodysostosis 10.0
332 rheumatic fever-related antigen 10.0
333 thrombocytopenia-absent radius syndrome 10.0
334 fabry disease 10.0
335 yemenite deaf-blind hypopigmentation syndrome 10.0
336 polydactyly 10.0
337 sickle cell anemia 10.0
338 alveolar soft part sarcoma 10.0
339 body mass index quantitative trait locus 1 10.0
340 pulmonary disease, chronic obstructive 10.0
341 allergic rhinitis 10.0
342 bulimia nervosa 10.0
343 coronary heart disease 4 10.0
344 platelet glycoprotein iv deficiency 10.0
345 hyperthyroidism, nonautoimmune 10.0
346 progressive external ophthalmoplegia with mitochondrial dna deletions, autosomal dominant 2 10.0
347 progressive external ophthalmoplegia with mitochondrial dna deletions, autosomal dominant 3 10.0
348 progressive external ophthalmoplegia with mitochondrial dna deletions, autosomal dominant 4 10.0
349 sick sinus syndrome 3 10.0
350 leptin deficiency or dysfunction 10.0
351 mucopolysaccharidosis-plus syndrome 10.0
352 multinodular goiter 10.0
353 tooth agenesis 10.0
354 fibroma 10.0
355 alexithymia 10.0
356 ptosis 10.0
357 inguinal hernia 10.0
358 mastoiditis 10.0
359 anal fistula 10.0
360 pollen allergy 10.0
361 anomalous left coronary artery from the pulmonary artery 10.0
362 congenital fiber-type disproportion 10.0
363 polycystic kidney disease 10.0
364 hypogonadotropic hypogonadism 10.0
365 migraine with aura 10.0
366 osteomyelitis 10.0
367 separation anxiety disorder 10.0
368 hypospadias 10.0
369 myopia 10.0
370 pyloric stenosis 10.0
371 transient global amnesia 10.0
372 nodular goiter 10.0
373 anodontia 10.0
374 familial hypercholesterolemia 10.0
375 gonadal dysgenesis 10.0
376 branchiootorenal syndrome 10.0
377 candidiasis 10.0
378 retinal vascular occlusion 10.0
379 hypogonadism 10.0
380 gaucher's disease 10.0
381 enthesopathy 10.0
382 hereditary multiple exostoses 10.0
383 iron metabolism disease 10.0
384 central retinal vein occlusion 10.0
385 retinal vascular disease 10.0
386 splenic infarction 10.0
387 lipid metabolism disorder 10.0
388 mood disorder 10.0
389 palmoplantar keratosis 10.0
390 turner syndrome 10.0
391 mixed connective tissue disease 10.0
392 tricuspid valve stenosis 10.0
393 systemic scleroderma 10.0
394 coronary stenosis 10.0
395 pustulosis of palm and sole 10.0
396 hypotrichosis 10.0
397 thyroid gland disease 10.0
398 sleep disorder 10.0
399 kidney disease 10.0
400 eye disease 10.0
401 discrete subaortic stenosis 10.0
402 hemolytic anemia 10.0
403 anterolateral myocardial infarction 10.0
404 anteroseptal myocardial infarction 10.0
405 phobic disorder 10.0
406 pulmonary valve stenosis 10.0
407 adenoma 10.0
408 juvenile rheumatoid arthritis 10.0
409 premenstrual tension 10.0
410 hypogonadotropism 10.0
411 end stage renal failure 10.0
412 carotid artery occlusion 10.0
413 polycythemia 10.0
414 ileus 10.0
415 retinal degeneration 10.0
416 psoriasis 10.0
417 autosomal dominant polycystic kidney disease 10.0
418 amyloidosis 10.0
419 exophthalmos 10.0
420 acute myocardial infarction 10.0
421 dextrocardia 10.0
422 alopecia 10.0
423 flna-related periventricular nodular heterotopia 10.0
424 hereditary multiple osteochondromas 10.0
425 trichorhinophalangeal syndrome 10.0
426 48,xyyy 10.0
427 acute articular rheumatism 10.0
428 banti's syndrome 10.0
429 coronary artery aneurysm 10.0
430 eales disease 10.0
431 frontometaphyseal dysplasia 10.0
432 haemophilus influenzae 10.0
433 hemiplegic migraine 10.0
434 mesomelia 10.0
435 pectus carinatum 10.0
436 pulmonary artery agenesis 10.0
437 ring chromosome 2 10.0
438 soft tissue sarcoma 10.0
439 back pain 10.0
440 cerebral aneurysms 10.0
441 encephalopathy 10.0
442 interatrial communication 10.0
443 temporomandibular joint anomaly 10.0
444 cardiogenic shock 10.0
445 cervical aortic arch 10.0
446 multiple sclerosis 9.9
447 erythermalgia, primary 9.9
448 hashimoto thyroiditis 9.9
449 pheochromocytoma 9.9
450 moyamoya disease 1 9.9
451 sudden infant death syndrome 9.9
452 ataxia and polyneuropathy, adult-onset 9.9
453 aging 9.9
454 resting heart rate, variation in 9.9
455 anxiety 9.9
456 hydrops, lactic acidosis, and sideroblastic anemia 9.9
457 segmental dystonia 9.9
458 adrenal gland pheochromocytoma 9.9
459 anhidrosis 9.9
460 autonomic nervous system disease 9.9
461 penile cancer 9.9
462 esophagitis 9.9
463 vestibular neuronitis 9.9
464 patent foramen ovale 9.9
465 squamous cell papilloma 9.9
466 benign paroxysmal positional nystagmus 9.9
467 neuritis 9.9
468 papilloma 9.9
469 gastritis 9.9
470 space motion sickness 9.9
471 dystonia 9.9
472 peripheral nervous system disease 9.9
473 thyroiditis 9.9
474 nervous system disease 9.9
475 diabetes mellitus 9.9
476 intracranial hypertension 9.9
477 47,xyy 9.9
478 mitochondrial disorders 9.9
479 baroreflex failure 9.9
480 lewis-sumner syndrome 9.9
481 brain injury 9.9
482 chronic pain 9.9
483 spinal cord injury 9.9
484 tremor 9.9
485 virus-associated trichodysplasia spinulosa 9.9
486 malignant tumor of penis 9.9
487 dysentery 9.8

Graphical network of the top 20 diseases related to Orthostatic Intolerance:



Diseases related to Orthostatic Intolerance

Symptoms & Phenotypes for Orthostatic Intolerance

Human phenotypes related to Orthostatic Intolerance:

31 (showing 1, show less)
# Description HPO Frequency HPO Source Accession
1 orthostatic tachycardia 31 HP:0012173

Clinical features from OMIM:

604715

UMLS symptoms related to Orthostatic Intolerance:


angina pectoris, edema, chest pain

MGI Mouse Phenotypes related to Orthostatic Intolerance:

45 (showing 5, show less)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.1 ADAM8 ADRA2A ADRA2B AGTR1 EDN1 FBN1
2 homeostasis/metabolism MP:0005376 10.07 ACHE ADAM8 ADRA2A ADRA2B AGTR1 EDN1
3 mortality/aging MP:0010768 9.97 ACHE ADRA2A ADRA2B AGTR1 EDN1 FBN1
4 muscle MP:0005369 9.5 ACHE ADRA2B EDN1 FBN1 NOS3 NOX4
5 renal/urinary system MP:0005367 9.17 ADRA2B AGTR1 EDN1 FBN1 NOS3 NOX4

Drugs & Therapeutics for Orthostatic Intolerance

PubMed Health treatment related to Orthostatic Intolerance: 62

Most people who have mitral valve prolapse (MVP) don't need treatment because they don't have symptoms and complications. Even people who do have symptoms may not need treatment . The presence of symptoms doesn't always mean that the backflow of blood through the valve is significant. People who have MVP and troublesome mitral valve backflow usually need treatment . MVP is treated with medicines, surgery , or both. The goals of treating MVP include: Preventing infective endocarditis (IE), arrhythmias , and other complications Relieving symptoms Correcting the underlying mitral valve problem, if necessary

Drugs for Orthostatic Intolerance (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(showing 187, show less)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
2
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
3
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
4
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
5 Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
6
Droxidopa Approved, Investigational Phase 4 23651-95-8 443940
7
Norepinephrine Approved Phase 4 51-41-2 439260
8
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
9
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3
10
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7
11 Adrenergic Agonists Phase 4
12 Vasoconstrictor Agents Phase 4
13 Gastrointestinal Agents Phase 4
14 Methylprednisolone Acetate Phase 4
15 Neuroprotective Agents Phase 4
16 Protective Agents Phase 4
17 Liver Extracts Phase 4
18 Autonomic Agents Phase 4
19 Antiemetics Phase 4
20 Anti-Inflammatory Agents Phase 4
21 Hormone Antagonists Phase 4
22 Antineoplastic Agents, Hormonal Phase 4
23 glucocorticoids Phase 4
24 Hormones Phase 4
25
protease inhibitors Phase 4
26 HIV Protease Inhibitors Phase 4
27 BB 1101 Phase 4
28
Midodrine Approved Phase 3 42794-76-3, 133163-28-7 4195
29
Nitric Oxide Approved Phase 2, Phase 3 10102-43-9 145068
30
Dopamine Approved Phase 3 51-61-6, 62-31-7 681
31
Methyldopa Approved Phase 3 555-30-6 38853
32
Metoclopramide Approved, Investigational Phase 3 364-62-5 4168
33
Levodopa Approved Phase 3 59-92-7 6047
34
Carbidopa Approved Phase 3 28860-95-9 34359
35
Nitroarginine Experimental, Investigational Phase 2, Phase 3 2149-70-4
36 NG-Nitroarginine Methyl Ester Phase 2, Phase 3
37 Sympathomimetics Phase 2, Phase 3
38 Antiparkinson Agents Phase 2, Phase 3
39 Dopamine Agents Phase 3
40 Adrenergic alpha-2 Receptor Agonists Phase 3
41 Atomoxetine Hydrochloride Phase 3
42 Dopamine D2 Receptor Antagonists Phase 3
43 Aromatic Amino Acid Decarboxylase Inhibitors Phase 3
44 alpha-methyltyrosine Phase 3
45 Dopamine Antagonists Phase 3
46 Pharmaceutical Solutions Phase 3
47 Plasma Substitutes Phase 3
48
Arginine Investigational, Nutraceutical Phase 2, Phase 3 74-79-3 6322
49
Estradiol Approved, Investigational, Vet_approved Phase 2 50-28-2 5757
50
Polyestradiol phosphate Approved Phase 2 28014-46-2
51
Progesterone Approved, Vet_approved Phase 2 57-83-0 5994
52
Ganirelix Approved Phase 2 124904-93-4, 123246-29-7 25081094
53
Epinephrine Approved, Vet_approved Phase 2 51-43-4 5816
54
Racepinephrine Approved Phase 2 329-65-7 838
55
Entacapone Approved, Investigational Phase 1, Phase 2 130929-57-6 5281081
56
AT-101 Approved, Investigational Phase 1, Phase 2 90141-22-3, 652-67-5 12597
57
Sertraline Approved Phase 1, Phase 2 79617-96-2 68617
58
Isosorbide Dinitrate Approved, Investigational Phase 1, Phase 2 87-33-2 6883
59
Acetazolamide Approved, Vet_approved Phase 1, Phase 2 59-66-5 1986
60
Octreotide Approved, Investigational Phase 1, Phase 2 83150-76-9 383414 6400441
61
Clonidine Approved Phase 1, Phase 2 4205-90-7 2803
62
Memantine Approved, Investigational Phase 1, Phase 2 19982-08-2 4054
63
Mecamylamine Approved, Investigational Phase 1, Phase 2 60-40-2 4032
64
Modafinil Approved, Investigational Phase 1, Phase 2 68693-11-8 4236
65
Indomethacin Approved, Investigational Phase 1, Phase 2 53-86-1 3715
66
Propranolol Approved, Investigational Phase 2 525-66-6 4946
67
Iron Approved, Experimental Phase 1, Phase 2 7439-89-6, 15438-31-0 23925 27284
68
Melatonin Approved, Nutraceutical, Vet_approved Phase 1, Phase 2 73-31-4 896
69 Estrogens Phase 2
70 Estradiol 17 beta-cypionate Phase 2
71 Contraceptive Agents Phase 2
72 Progestins Phase 2
73 Estradiol 3-benzoate Phase 2
74 Epinephryl borate Phase 2
75 Melanocyte-Stimulating Hormones Phase 1, Phase 2
76 Corticotropin-Releasing Hormone Phase 1, Phase 2
77 beta-endorphin Phase 1, Phase 2
78 Adrenocorticotropic Hormone Phase 1, Phase 2
79 Serotonin Uptake Inhibitors Phase 1, Phase 2
80 Analgesics Phase 1, Phase 2
81 Central Nervous System Depressants Phase 1, Phase 2
82 isosorbide-5-mononitrate Phase 1, Phase 2
83 Catechol O-Methyltransferase Inhibitors Phase 1, Phase 2
84 Central Nervous System Stimulants Phase 1, Phase 2
85 Cytochrome P-450 CYP3A Inducers Phase 1, Phase 2
86 Antioxidants Phase 1, Phase 2
87 Anti-Inflammatory Agents, Non-Steroidal Phase 1, Phase 2
88 Analgesics, Non-Narcotic Phase 1, Phase 2
89 Catechol Phase 1, Phase 2
90 Psychotropic Drugs Phase 1, Phase 2
91 Tocolytic Agents Phase 1, Phase 2
92 Cholinergic Agents Phase 1, Phase 2
93 Carbonic Anhydrase Inhibitors Phase 1, Phase 2
94 Antirheumatic Agents Phase 1, Phase 2
95 Anticonvulsants Phase 1, Phase 2
96 Natriuretic Agents Phase 1, Phase 2
97 Excitatory Amino Acid Antagonists Phase 1, Phase 2
98 Excitatory Amino Acids Phase 1, Phase 2
99 Antidepressive Agents Phase 1, Phase 2
100 Serotonin Agents Phase 1, Phase 2
101 Cholinergic Antagonists Phase 1, Phase 2
102 Nitric Oxide Donors Phase 1, Phase 2
103 diuretics Phase 1, Phase 2
104 Cyclooxygenase Inhibitors Phase 1, Phase 2
105 Neurotransmitter Agents Phase 2
106 Adrenergic Agents Phase 2
107 Anti-Arrhythmia Agents Phase 2
108 Adrenergic Antagonists Phase 2
109 Antihypertensive Agents Phase 2
110 Adrenergic beta-Antagonists Phase 2
111 Vasodilator Agents Phase 2
112 Sympatholytics Phase 1, Phase 2
113 Micronutrients Phase 1, Phase 2
114 Trace Elements Phase 1, Phase 2
115 Nutrients Phase 1, Phase 2
116 Adrenergic beta-1 Receptor Antagonists Phase 1, Phase 2
117 Hematinics Phase 1, Phase 2
118 Ferric Oxide, Saccharated Phase 1, Phase 2
119
Serotonin Investigational, Nutraceutical Phase 1, Phase 2 50-67-9 5202
120
Angiotensin II Approved, Investigational Phase 1 68521-88-0, 4474-91-3, 11128-99-7 172198
121
Trimethaphan Approved, Investigational Phase 1 7187-66-8 23576
122
Atropine Approved, Vet_approved Phase 1 5908-99-6, 51-55-8 174174
123
Pseudoephedrine Approved Phase 1 90-82-4 7028
124
Ephedrine Approved Phase 1 299-42-3 9294
125
Phenylephrine Approved Phase 1 59-42-7 6041
126
Oxymetazoline Approved, Investigational Phase 1 1491-59-4 4636
127
Isoproterenol Approved, Investigational Phase 1 7683-59-2 3779
128
Nitroprusside Approved, Investigational Phase 1 15078-28-1 11963622
129
Yohimbine Approved, Investigational, Vet_approved Phase 1 146-48-5 8969